Public Workshop of the Committee on Medication-Assisted Treatment for Opioid Use Disorder

Draft Agenda

Keck Center
E Street Conference Room
500 5th St NW
Washington DC 20001

October 30 – 31, 2018

STATEMENT OF TASK

To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, an ad hoc committee under the auspices of the National Academies of Sciences, Engineering, and Medicine will conduct a study of the evidence base on medication-assisted treatment (MAT) for opioid use disorder (OUD). Specifically, the committee will:

- Review current knowledge and gaps in understanding regarding the effectiveness of MAT for treating OUD,
- Examine available evidence on the range of parameters and circumstances in which MAT can be effectively delivered (e.g., duration of treatment, populations, settings, and Interventions to address social determinants of health (SDH) as a component of MAT),
- Identify challenges in implementation and uptake, and
- Identify additional research needed on MAT for OUD.

Based on its review of the literature and input from the public workshop, the committee will develop a report with its findings and conclusions.
## OPEN SESSION

**8:30 am**  
Welcome and opening remarks  
- **Alan Leshner**, Committee Chair, Emeritus of the American Association for the Advancement of Science (AAAS)  
- **Victor Dzau**, National Academy of Medicine

**8:45am**  
**Keynote (15 minutes)**  
- **Brett Giroir**, Assistant Secretary for Health, U.S. Department of Health and Human Services *(confirmed)*

### SESSION 1: FEDERAL INITIATIVES

**90 minute session (brief 5-7 minute panelist presentations followed by moderated discussion and Q&A)**

**9:00am**  
**Objectives:** Discuss current federal efforts to improve treatment for opioid use disorder and access to medication assisted treatment, and hear perspectives from the study sponsors, NIDA and SAMHSA.  
**Moderator:** **Alan Leshner**, Committee Chair, Emeritus of the American Association for the Advancement of Science (AAAS)  
**Panelists:**  
- **Nora Volkow**, National Institute on Drug Abuse *(confirmed)*  
- **Deepa Avula**, Substance Abuse and Mental Health Services Administration *(confirmed)*  
- **Molly Evans**, Centers for Disease Control and Prevention *(confirmed)*  
- **Judith Steinberg**, Health Resources and Services Administration *(confirmed)*  
- **Rigo Roca**, Food and Drug Administration *(confirmed)*

**10:30am**  
BREAK

### SESSION 2: CURRENT EVIDENCE AND PRACTICE ON MEDICATION FOR TREATING OPIOID USE DISORDER

**120 minutes (25 minute opening presentation followed by moderated panel discussion)**

**10:45am**  
**Objectives:**  
- Discuss current evidence on the effectiveness of specific medications used to treat opioid use disorder (OUD).
- Identify evidence gaps that might contribute to limited effectiveness of specific medications or limit the use of medications in treating OUD, i.e. dosing ranges, optimal duration of treatments, discontinuation, optimal duration of tapering medication, and real-world evidence on patient experiences and preferences.

- For each medication, examine the regulations, infrastructure, and care settings required for delivery of specific medications for OUD and explore how this influences patient and provider preference when selecting treatment.

- Discuss the evidence for behavioral counseling as a component of treatment for OUD. Are the current requirements for counseling evidence-based?

- Identify barriers to the use of specific medications, including any long term side effects of medications for treating OUD and the perception and stigma of treatment options by patients, providers, the general public, and law enforcement.

**Moderator:** Kathleen Carroll, Yale School of Medicine

**Opening Presentation:**

- **Charles O’Brien**, University of Pennsylvania (*confirmed*)

**Panelists:**

- **John Brooklyn**, University of Vermont (*confirmed*)
- **Michelle Lofwall**, University of Kentucky (*confirmed*)
- **Gavin Bart**, University of Minnesota (*confirmed*)
- **Maia Szalavitz**, American reporter and author (*confirmed*)

12:45pm  LUNCH

**SESSION 3: IMPLEMENTATION AND UPTAKE – OPPORTUNITIES AND BARRIERS**

1:45pm  Panel 3a: Opportunities and barriers – Education and training to expand treatment

(*brief 5-7 minute panelist presentations followed by moderated discussion and Q&A*)

**Objectives:**

- Examine the currently required education and training for providers treating opioid use disorder and identify best practices and hurdles to achieving the required workforce to treat OUD

- Explore the makeup of an ideal OUD treatment workforce and discuss how this workforce may change based on care settings, populations, regions, and availability of medication for the treatment of OUD
- Consider educational requirements for clinicians (surgical services, primary care, emergency departments, pharmacists), counselors, social workers and others
- Discuss what patient and family education or resources should be provided
- Identify best practices and education for policy makers, law enforcement, the public and other stakeholders

**Moderator:** Chinazo Cunningham, Albert Einstein College of Medicine

**Panelists:**
- **Jeannette Tetrault,** Yale University (confirmed)
- **Stephen Patrick,** Vanderbilt University (confirmed)
- **Eugenia Oviedo-Joekes,** University of British Columbia (confirmed)
- **Jules Netherland,** Drug Policy Alliance (confirmed)
- **Kathleen Johnson,** Advocates for Opioid Recovery (confirmed)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:15pm</td>
<td>BREAK</td>
</tr>
<tr>
<td>3:30pm</td>
<td>Panel 3b: Opportunities and barriers – Health care delivery, payment approaches, and economics measures to improve treatment of OUD</td>
</tr>
</tbody>
</table>
  
  *90 minutes (15 minute opening presentation followed by moderated panel discussion)*

**Objectives:**
- Discuss how health care access and delivery impact patient access to medications to treat OUD, consider regulations around hospital capacity, administrative burdens, and the tight regulation of medical products
- Explore the cost, reimbursement, and coverage of medications to treat OUD and discuss measures to help facilitate quality improvement and access
- Examine regulatory differences of for-profit versus non-profit treatment providers

**Moderator:** Colleen Barry, Johns Hopkins School of Public Health

**Opening Presentation:**
- **Richard Frank,** Harvard University (confirmed)

**Panelists:**
- **H. Westley Clark,** Santa Clara University (invited)
- **Kelly J. Clark,** American Society of Addiction Medicine (invited)
- **Allan Coukell,** Pew Charitable Trust (confirmed)
5:00pm  Day 1 recap and closing remarks

- **Katrina King**, George Mason University (*confirmed*)
- **Alan Leshner**, Committee Chair, Emeritus of the American Association for the Advancement of Science (AAAS)

5:15pm  ADJOURN

### DAY 2: October 31, 2018
Keck Center  
E Street Conference Room  
500 5th St NW  
Washington DC 20001

**OPEN SESSION**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| **8:30 am** | Welcome and opening remarks  
- **Alan Leshner**, Committee Chair, Emeritus of the American Association for the Advancement of Science (AAAS) |
| **8:45 am** | **Objectives:**  
- Explore the impact of comorbidities on treatment and how this may impact the uptake and overall effectiveness of medications to treat opioid use disorder  
- Consider how pregnancy, age, race, gender, genetic variables, mental health, chronic pain, and other factors may influence treatment  
- Identify further evidence needed to better deliver culturally appropriate care and serve diverse populations  
**Moderator:** **David Patterson Silver Wolf**, Washington University  
**Panelists:**  
- **Helena B. Hansen**, NYU (*confirmed*)  
- **Josiah Rich**, Brown University (*confirmed*)  
- **Anand Kumar**, University of Illinois Chicago (*confirmed*)  
- **Mishka Terplan**, Virginia Commonwealth University (*confirmed*) |
## SESSION 4: Knowledge gaps – Future research and next steps

### 90 minute session (brief 5-7 minute panelist presentations followed by moderated discussion and Q&A)

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30am</td>
<td><strong>Objectives:</strong></td>
</tr>
<tr>
<td></td>
<td>Discuss required research on FDA approved and non-FDA approved medications for the treatment of OUD, consider patient preferences, delivery mechanisms, patient population (e.g., demographics or severity of OUD), and how different treatment settings may impact the research required</td>
</tr>
<tr>
<td></td>
<td>Identify patient outcome measures and process measures to facilitate the development of best practices for treating OUD</td>
</tr>
<tr>
<td></td>
<td>Identify research needs and policy changes to advance treatment and recovery</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Yasmin Hurd, Icahn School of Medicine at Mount Sinai</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists:</strong></td>
</tr>
<tr>
<td></td>
<td>Gail D’Onofrio, Yale University <em>(confirmed)</em></td>
</tr>
<tr>
<td></td>
<td>Jonathan H. Watanabe, UCSD <em>(confirmed)</em></td>
</tr>
<tr>
<td></td>
<td>Sharon Walsh, University of Kentucky <em>(confirmed)</em></td>
</tr>
<tr>
<td></td>
<td>Jessica Hulsey Nickel, Addiction Policy Forum <em>(confirmed)</em></td>
</tr>
<tr>
<td>12:00pm</td>
<td><strong>Objective:</strong></td>
</tr>
<tr>
<td></td>
<td>Members of the public are invited to sign up to provide comments on the workshop topic (3 minutes each)</td>
</tr>
<tr>
<td></td>
<td><strong>Moderator:</strong> Alan Leshner, Committee Chair, Emeritus of the American Association for the Advancement of Science (AAAS)</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Meeting recap and closing remarks</td>
</tr>
<tr>
<td></td>
<td>Alan Leshner, Committee Chair, Emeritus of the American Association for the Advancement of Science (AAAS)</td>
</tr>
<tr>
<td>12:45pm</td>
<td>ADJOURN</td>
</tr>
</tbody>
</table>